Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib

Isabel M. Haugh; Ian T. Watson; M. Alan Menter

doi:10.1080/08998280.2018.1480246

Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib

Isabel M. Haugh, Ian T. Watson, M. Alan Menter

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. JAK1 plays a central role in expression of proinflammatory cytokines IL-4, IL-5, and IL-13, which play an important role in the pathogenesis of atopic dermatitis. Ruxolitinib and tofacitinib are JAK inhibitors currently approved by the Food and Drug Administration for the treatment of myelofibrosis, rheumatoid arthritis, and psoriatic arthritis in humans. Oclacitinib is not currently indicated for use in humans.

Original language	English (US)
Pages (from-to)	524-525
Number of pages	2
Journal	Baylor University Medical Center Proceedings
Volume	31
Issue number	4
DOIs	https://doi.org/10.1080/08998280.2018.1480246
State	Published - Oct 2 2018
Externally published	Yes

Keywords

Atopic dermatitis
JAK1
eczema
oclacitinib

ASJC Scopus subject areas

General Medicine

Access to Document

10.1080/08998280.2018.1480246

Cite this

@article{52d6ee47f4d24d8eab13758f43c12957,

title = "Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib",

abstract = "We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. JAK1 plays a central role in expression of proinflammatory cytokines IL-4, IL-5, and IL-13, which play an important role in the pathogenesis of atopic dermatitis. Ruxolitinib and tofacitinib are JAK inhibitors currently approved by the Food and Drug Administration for the treatment of myelofibrosis, rheumatoid arthritis, and psoriatic arthritis in humans. Oclacitinib is not currently indicated for use in humans.",

keywords = "Atopic dermatitis, JAK1, eczema, oclacitinib",

author = "Haugh, {Isabel M.} and Watson, {Ian T.} and {Alan Menter}, M.",

note = "Funding Information: No funding was provided by any source for this project. Dr. Menter reports grants and honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, and Xenoport; grants from Anacor, Celgene, Dermira, Merck, Neothetics, Regeneron, and Symbio/Maruho; and honoraria from Eli Lilly, Galderma, and Vitae, all outside of the submitted work. The remaining authors do not have funding disclosures, financial support, or industrial affiliations to report regarding any materials or methods used in this study or the findings indicated in this manuscript. Publisher Copyright: {\textcopyright} 2018, Copyright {\textcopyright} 2018 Baylor University Medical Center.",

year = "2018",

month = oct,

day = "2",

doi = "10.1080/08998280.2018.1480246",

language = "English (US)",

volume = "31",

pages = "524--525",

journal = "Baylor University Medical Center Proceedings",

issn = "0899-8280",

publisher = "Taylor and Francis Ltd.",

number = "4",

}

TY - JOUR

T1 - Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib

AU - Haugh, Isabel M.

AU - Watson, Ian T.

AU - Alan Menter, M.

N1 - Funding Information: No funding was provided by any source for this project. Dr. Menter reports grants and honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Janssen Biotech, Inc., LEO Pharma, Novartis, Pfizer, and Xenoport; grants from Anacor, Celgene, Dermira, Merck, Neothetics, Regeneron, and Symbio/Maruho; and honoraria from Eli Lilly, Galderma, and Vitae, all outside of the submitted work. The remaining authors do not have funding disclosures, financial support, or industrial affiliations to report regarding any materials or methods used in this study or the findings indicated in this manuscript. Publisher Copyright: © 2018, Copyright © 2018 Baylor University Medical Center.

PY - 2018/10/2

Y1 - 2018/10/2

N2 - We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. JAK1 plays a central role in expression of proinflammatory cytokines IL-4, IL-5, and IL-13, which play an important role in the pathogenesis of atopic dermatitis. Ruxolitinib and tofacitinib are JAK inhibitors currently approved by the Food and Drug Administration for the treatment of myelofibrosis, rheumatoid arthritis, and psoriatic arthritis in humans. Oclacitinib is not currently indicated for use in humans.

AB - We report the first case of atopic dermatitis successfully treated with the oral Janus kinase-1 (JAK1) inhibitor oclacitinib. A man in his 70s, with a 6-year history of skin disease refractory to topical and biologic therapies, self-prescribed this veterinary medication with rapid remission of symptoms. He has remained in remission for 7 months with no reported adverse side effects or infections. JAK1 plays a central role in expression of proinflammatory cytokines IL-4, IL-5, and IL-13, which play an important role in the pathogenesis of atopic dermatitis. Ruxolitinib and tofacitinib are JAK inhibitors currently approved by the Food and Drug Administration for the treatment of myelofibrosis, rheumatoid arthritis, and psoriatic arthritis in humans. Oclacitinib is not currently indicated for use in humans.

KW - Atopic dermatitis

KW - JAK1

KW - eczema

KW - oclacitinib

UR - http://www.scopus.com/inward/record.url?scp=85053683392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053683392&partnerID=8YFLogxK

U2 - 10.1080/08998280.2018.1480246

DO - 10.1080/08998280.2018.1480246

M3 - Article

C2 - 30949000

AN - SCOPUS:85053683392

SN - 0899-8280

VL - 31

SP - 524

EP - 525

JO - Baylor University Medical Center Proceedings

JF - Baylor University Medical Center Proceedings

IS - 4

ER -

Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this